Trials / NCT01543906
Oral QLT091001 in Retinitis Pigmentosa (RP) Subjects With an Autosomal Dominant Mutation in Retinal Pigment Epithelial 65 Protein (RPE65)
Completed Phase 1 Drug / neuroprotection
- Sponsor
- QLT Inc.
- Treatment
- QLT091001
- Gene
- RPE65
- Conditions
- Retinitis Pigmentosa (RP)
- Ages
- 18 Years to 70 Years
- Enrollment
- 5 participants
- Started
- 2012-02
- Main results expected
- 2014-07
- Results posted
- Not yet
- Record last updated
- 2014-12-15
What the study is testing
The purpose of this study is:
- To evaluate whether 7-day treatment with oral QLT091001 can improve visual function in RP subjects with an autosomal dominant mutation in RPE65.
- To evaluate duration of visual function improvement (if observed) in RP subjects with an autosomal dominant mutation in RPE65 after 7-day treatment with oral QLT091001.
- To evaluate the safety of oral QLT091001 administered once daily for 7 days in RP subjects with an autosomal dominant mutation in RPE65.
Where it runs
Canada (1)
- Montreal Children's Hospital, McGill University Health Centre, Montreal, Quebec
Ireland (1)
- Royal Victoria Eye and Ear Hospital, Dublin